



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/914,088	11/13/2001	Michael Dyson	B45172	9241
20462	7590	11/20/2003		
SMITHKLINE BEECHAM CORPORATION CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939			EXAMINER HUYNH, PHUONG N	
			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 11/20/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/914,088	DYSON ET AL.	
	Examiner	Art Unit	
	Phuong Huynh	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE Three MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 30 September 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 42-83 is/are pending in the application.
- 4a) Of the above claim(s) 44-50, 53-57 and 68-83 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 42, 43, 51, 52 and 58-67 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☒ All b) ☐ Some c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- | | |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>8/22/01</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Claims 42-83 are pending.
2. Applicant's election with traverse of Group I, Claims 42-43, 51-52 and 58-67, drawn to an isolated peptide comprising SEQ ID NO: 1, filed 9/30/03, is acknowledged. The traversal is on the grounds that (1) while the groups identified may be distinct, they are not independent because search terms for one group will necessarily be shared with other groups. (2) Applicants submit that under unity of invention, claims 42-43, 50-55, 58-67 and 75-83 are related as a product, a process specially adapted for manufacture of said product, and a use of said product. This is not found persuasive because (1) while a search of the different inventions may be overlapping, they are not coextensive and a different field of search would be required based upon the structurally distinct products recited. (2) The invention of Group I was found to have no special technical feature over the prior art. Basu *et al* (J Biol Chem 268(18): 13118-13127, 1993; PTO 892) teach various peptide and peptide mimotope comprising an isolated Cε2 domain of IgE such as Fce (315-547) containing the entire Cε2-Cε4 (235-547), Fce3(236-438) contains the last 15 amino acids of Cε2 (See page 13121, column 1, Figure 1, in particular). Further, a prior art search also requires a literature search. It is a burden to search more than one invention. Therefore, the requirement of Group 1 and Groups 2-96 is still deemed proper and is therefore made FINAL.
3. Claims 44-50, 53-57 and 68-83 are withdrawn from further consideration by the examiner, 37 C.F.R. 1.142(b) as being drawn to non-elected inventions.
4. Claims 42-43, 51-52 and 58-67, drawn to drawn to an isolated peptide comprising SEQ ID NO: 1, are being acted upon in this Office Action.
5. Claims 42-43, 58, and 60-62 are objected to for reciting non-elected embodiment.
6. Claims 58 and 60 are objected to because said claims are depended from non-elected claims 44-57.

Art Unit: 1644

7. Claims 43, 51, 52, 59, 60, 61, 62, and 64-67 are objected to because "A" should have been "The" in dependent claims.
8. The following is a quotation of the first paragraph of 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
9. Claims 42-43, 51-52 and 58-67 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling only for (1) a peptide consisting of an isolated surface exposed epitope of the Cε2 domain of IgE wherein the surface exposed epitope consisting of Cε2 is P1 (SEQ ID NO: 1), (2) The said peptide wherein the isolated epitope is derived from a loop structure of the Cε2 domain of IgE, (3) The said peptide wherein the loop structure of the Cε2 domain of IgE is the A-B or the C-D loop, (4) A composition comprising an immunogen for the treatment of allergy wherein the immunogen consists of a peptide consisting of Cε2 is P1 (SEQ ID NO: 1), and a carrier molecule, (5) The composition mentioned above wherein the carrier molecule is selected from Protein D or Hepatitis B core antigen, (6) An immunogen for the treatment of allergy comprising a peptide consisting of SEQ ID NO: 1 chemically conjugated or fused to a carrier molecule, (7) The immunogen for the treatment of allergy comprising a peptide consisting of SEQ ID NO: 1 chemically conjugated or fused to a carrier molecule wherein said peptide is presented within the primary sequence of the carrier, and (8) A vaccine for the treatment of allergy comprising a peptide consisting of an isolated surface exposed epitope of the Cε2 domain of IgE wherein the surface exposed epitope consisting of Cε2 is P1 (SEQ ID NO: 1), and a carrier molecule and further comprising an adjuvant for inducing autoanti-IgE antibodies, **does not** reasonably provide enablement for (1) *any* peptide "comprising" any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* "mimotope" thereof, (2) *any* peptide "comprising" any isolated surface exposed epitope of the Cε2 domain of IgE, wherein the surface exposed epitope of Cε2 "is" P1 (SEQ ID NO: 1), or *any* "mimotope" thereof, (3) the peptide "comprising" any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* "mimotope" thereof wherein the isolated epitope is derived from any loop structure of the Cε2 domain of IgE, (4) the peptide "comprising" any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* "mimotope" thereof wherein the loop structure of the Cε2 domain of IgE is the A-B or the C-D loop, (5) *any* immunogen for the treatment of allergy comprising *any* peptide "comprising" *any*

isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1), additionally “comprising” a carrier molecule, (6) the immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1), additionally “comprising” a carrier molecule wherein the carrier is selected from Protein D or Hepatitis B core antigen, (7) *any* immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1) wherein the immunogen is a chemical conjugate of the peptide or the mimotope thereof or wherein the immunogen is expressed as a fusion protein and a carrier molecule, (8) the immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1), additionally “comprising” a carrier molecule wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier, (9) the immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1) wherein the immunogen is a chemical conjugate of the peptide or the mimotope thereof or wherein the immunogen is expressed as a fusion protein and a carrier molecule wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier, and (10) a vaccine for the treatment of allergy comprising *any* immunogens mentioned above, and further comprising an adjuvant for treating allergy. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in **scope** with these claims.

Factors to be considered in determining whether undue experimentation is required to practice the claimed invention are summarized *In re Wands* (858 F2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)). The factors most relevant to this rejection are the scope of the claim, the amount of direction or guidance provided, the lack of sufficient working examples, the unpredictability in the art and the amount of experimentation required to enable one of skill in the art to practice the claimed invention. The specification disclosure is insufficient

to enable one skilled in the art to practice the invention as broadly claimed without an undue amount of experimentation.

The specification discloses only a peptide consisting of an isolated surface exposed epitope of the Cε2 domain of IgE wherein the surface exposed epitope consisting of Cε2 is P1 (SEQ ID NO: 1) and peptide mimotope of P1 selected from the group consisting of SEQ ID NO: 8-9, 10-28, and 192-193 as shown on page 9 either conjugated to a carrier protein such as BSA or fused to HepB core protein for inducing anti-IgE antibody for treating allergy. The specification defines mimotope may be a peptidic or non-peptidic, or may have a sequence which differs from the native epitope but may also be exactly the same sequence as the native epitope. Although the two molecules share the same sequence, the mimotope will not be presented in the context of the whole Cε2 domain structure, as such the mimotope may take a slightly different conformation to the native IgE epitope (page 5, lines 18-25).

The specification does not teach how to make and use *any* peptide or *any* mimotope mentioned above for treatment of allergy or vaccine because (1) the terms “peptide” and “mimotope” without the specific amino acid sequence (SEQ ID NO) have no structure, much less function, let alone a mimotope may be a nonpeptide, or may have a sequence which differs from the native epitope or different conformation. Further, the term “comprising” is open ended. It expands the undisclosed peptide or undisclosed mimotope to include additional amino acids at either or both ends. There is insufficient guidance as to which undisclosed amino acid to be added and whether the resulting peptide or mimotope will maintain the same structure and function as the native peptide of SEQ ID NO: 1, in turn, would induce IgE specific antibody that is useful as a vaccine for treating allergy.

Stryer *et al* teach that a protein is highly dependent on the overall structure of the protein itself and that the primary amino acid sequence determines the conformation of the protein (See enclosed appropriate pages).

Ngo *et al* teach that the amino acid positions within the polypeptide/protein that can tolerate change such as conservative substitution or no substitution, addition or deletion which are critical to maintain the protein's structure/function will require guidance (See Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495).

Skolnick *et al* teach that sequence-based methods for function prediction are inadequate and knowing a protein's structure does not necessarily tell one its function (See entire document, Abstract in particular).

Abaza *et al* teach that even a single amino acid substitution outside the antigenic site can exert drastic effects on the reactivity of a protein with monoclonal antibody against the site (See abstract, in particular). Given the indefinite number of undisclosed peptide and mimotope, it is unpredictable which undisclosed peptide and mimotope would be useful for generating anti-IgE antibody that in turn would be useful for a vaccine against allergy. In fact, the specification discloses that “whether or not an antibody is anaphylactogenic depends on the location of the target epitope on the IgE molecule ...based on the present state of knowledge, there is little or no predictability of what characteristics any antibody may have and whether or not it might have a positive or negative clinical effect on a patient” (see paragraph bridging page 2 to 3 of specification).

For these reasons, it would require undue experimentation of one skilled in the art to practice the claimed invention. See page 1338, footnote 7 of *Ex parte Aggarwal*, 23 USPQ2d 1334 (PTO Bd. Pat App. & Inter. 1992).

In re wands, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988), the decision of the court indicates that the more unpredictable the area is, the more specific enablement is necessary. In view of the quantity of experimentation necessary, the limited working examples, the unpredictability of the art, the lack of sufficient guidance in the specification and the breadth of the claims, it would take an undue amount of experimentation for one skilled in the art to practice the claimed invention.

10. Claims 42-43, 51-52 and 58-67 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

The specification does not reasonably provide a **written description** of (1) *any* peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, (2) *any* peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, wherein the surface exposed epitope of Cε2 “is” P1 (SEQ ID NO: 1), or *any* “mimotope” thereof, (3) the peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof wherein the isolated epitope is derived from any loop structure of the Cε2 domain of IgE, (4) the peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof wherein the loop structure of the Cε2 domain of

Art Unit: 1644

IgE is the A-B or the C-D loop, (5) *any* immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1), additionally “comprising” a carrier molecule, (6) the immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1), additionally “comprising” a carrier molecule wherein the carrier is selected from Protein D or Hepatitis B core antigen, (7) *any* immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1) wherein the immunogen is a chemical conjugate of the peptide or the mimotope thereof or wherein the immunogen is expressed as a fusion protein and a carrier molecule, (8) the immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1), additionally “comprising” a carrier molecule wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier, (9) the immunogen for the treatment of allergy comprising any peptide “comprising” any isolated surface exposed epitope of the Cε2 domain of IgE, or *any* “mimotope” thereof, or any peptide wherein the surface exposed epitope of Cε2 domain of IgE “is P1” (SEQ ID NO: 1) wherein the immunogen is a chemical conjugate of the peptide or the mimotope thereof or wherein the immunogen is expressed as a fusion protein and a carrier molecule wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier, and (10) a vaccine for the treatment of allergy comprising *any* immunogens mentioned above, and further comprising an adjuvant for treating allergy.

The specification discloses only a peptide consisting of an isolated surface exposed epitope of the Cε2 domain of IgE wherein the surface exposed epitope consisting of Cε2 is P1 (SEQ ID NO: 1) and peptide mimotope of P1 selected from the group consisting of SEQ ID NO: 8-9, 10-28, and 192-193 as shown on page 9 either conjugate to a carrier protein such as BSA or fuse to HepB core protein for induce anti-IgE treating allergy. The specification defines mimotope may be a peptidic or non-peptidic, or may have a sequence which differs from the native epitope but may also be exactly the same sequence as the native epitope. Although the two

molecules share the same sequence, the mimotope will not presented in the context of the whole Cε2 domain structure, as such the mimotope may take a slightly different conformation to the native IgE epitope (page 5, lines 18-25).

With the exception of the specific peptide and peptide mimotope mentioned above, there is inadequate written description about the structure associated with function of *any* peptide, or *any* "mimotope" thereof "comprising" any isolated surface exposed epitope of the Cε2 domain of IgE, because the term "peptide" and "mimotope" without the specific amino acid sequence have no structure, much less about its function. Further, the term "comprising" is open ended. It expands the undisclosed peptide and mimotope thereof to include additional amino acid at either or both ends. There is inadequate written description about which undisclosed amino acids to be added and whether the resulting peptide or mimotope could be useful for inducing IgE specific antibody as a vaccine for treatment of allergy. In re Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111 indicates that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the written description inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.). Finally, the specification discloses only one P1 peptide consisting of SEQ ID NO: 1 from human. Given the lack of a written description of *any* additional representative species of surface exposed epitope of Cε2 is a P1 peptide, one of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus. Thus, Applicant was not in possession of the claimed genus. See *University of California v. Eli Lilly and Co.* 43 USPQ2d 1398.

Applicant is directed to the Revised Interim Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001.

11. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Art Unit: 1644

12. Claims 58, 59, 61, 63, 64 and 66 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The “immunogen” in claim 58 is ambiguous and indefinite because the claim as written reads on a composition and not an immunogen. Further, immunogen does not have a carrier.

13. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

14. Claims 42-43 and 51-52 are rejected under 35 U.S.C. 102(b) as being anticipated by Basu *et al* (J Biol Chem 268(18): 13118-13127, 1993; PTO 892).

Basu *et al* teach various peptide and peptide mimotope comprising an isolated Cε2 domain of IgE such as Fcε (315-547) containing the entire Cε2-Cε4 (235-547), Fcε3(236-438) domains that contain the last 15 amino acids of Cε2 (See page 13121, column 1, Figure 1, in particular). The IgE Cε2 domain of the reference peptide inherently contains the surface exposed epitope. Claim 43 is included in this rejection because the term “comprising” is open ended. It expands the claimed peptide of SEQ ID NO: 1 to read on the reference peptides. Claims 51-52 are included in this rejection because the AB or CD loop structure is an inherent structure of the IgE constant domain to which the reference peptide is obtained. Thus, the reference teachings anticipate the claimed invention.

Art Unit: 1644

15. Claims 42-43, 51-52, 58, 60, 63, and 65 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 93/05810 (April 1993, PTO 892).

The WO 93/05810 publication teaches various peptides such as rat or human IgE CH2-CH3, which comprises an isolated Cε2 domain of IgE for a vaccine for treating allergy (See abstract, claims 1 and 5 of WO 93/05810, page 14, in particular). The IgE Cε2 domain of the reference peptide inherently contains the surface exposed epitope (solvent accessible). Claim 43 is included in this rejection because the term comprising is open ended. It expands the claimed peptide of SEQ ID NO: 1 to read on the reference peptide. The WO 93/05810 publication further teaches an immunogen such as the reference peptide optionally conjugated (coupled) or fused to a heterologous carrier protein such as GST and optionally with an adjuvant such as alum (See abstract, claim 1 and 2 of WO 93/05810, page 7, line 32, in particular). Claims 51-52 are included in this rejection because the AB or CD loop structure is an inherent structure of the IgE constant domain to which the reference peptide is obtained. Thus, the reference teachings anticipate the claimed invention.

16. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 103(a) that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

17. This application currently names joint inventors. In considering Patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1644

18. Claims 42, 43, 58, 59, and 60- 67 are rejected under 35 U.S.C. 103(a) as being unpatentable over Basu *et al* (J Biol Chem 268(18): 13118-13127, 1993; PTO 892) or WO 93/05810 (April 1993, PTO 892) each in view of Ulrich *et al* (Adv Virus Res 50:141-82, 1998; PTO 892) or US Pat No 4,593,002 (June 1986; PTO 892)

The teachings of Basu *et al* and the WO 93/05810 publication have been discussed *supra*.

The claimed invention in claim 59 differs from the teachings of the references only that an immunogen wherein the carrier molecule is Hepatitis B core antigen or Protein D.

The claimed invention in claims 61 and 62 differs from the teachings of the references only that an immunogen wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier.

The claimed invention in claims 64, 66 and 67 differs from the teachings of the references only that the vaccine for treatment of allergy comprising an immunogen comprising a peptide or mimotope wherein the immunogen is a chemically conjugate of the peptide or the mimotope or wherein the immunogen is expressed as a fusion protein and further comprising an adjuvant.

Ulrich *et al* teach that core protein of hepatitis B (HbcAg) is useful as an immunogenic antigen carrier since up to 40 amino acid residues at the N terminus, 50 or 100 amino acids in the central immunodominant c/e1 epitope region of HbcAg and up to 100 or even more residues at the C terminus can be inserted without interfering particle formation (See abstract, in particular). Ulrich *et al* teach that when applied together with adjuvant or even without adjuvant, such chimeric particles induced B and T cell immune responses against the inserted epitopes (See abstract, in particular).

The '002 patent teaches the use of various carrier such as protein D for vaccine composition to enhance immunogenicity of any immunogen (See entire document, column 4, line 41-45, in particular). The '002 patent teaches that the peptide is inserted within the primary sequence of the carrier in such as way that the peptide or protein of interest is exposed to the outside of the phage coat and accessible to the immune system of the vaccinated host (See column 8, in particular). The '002 patent teaches that the advantage of carrier is that it functions for enhance immunogenicity, providing protein stability and retains the ability to replicate while the incorporated protein segment has the potential for inducing the specific immune response (See column 2, lines 55-62, in particular).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to conjugate or to fuse any peptide or mimotope of interest such as the peptide as taught by Basu *et al* or the WO 93/05810 publication with a carrier such as the Hepatitis B core antigen as taught by Ulrich *et al* or the Protein D of Haemophilus influenza as taught by Mustafa *et al* where the peptide or peptide mimotope is within the primary sequence of the carrier as taught by Ulrich *et al* for a vaccine comprising said peptide, said carrier and an adjuvant as taught by Basu *et al*, the WO 93/05810 publication, Ulrich *et al* and/or Mustafa *et al*. From the combined teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention.

One having ordinary skill in the art would have been motivated to do this because Ulrich *et al* teach that core protein of hepatitis B (HbcAg) is useful as an immunogenic antigen carrier since 50 or 100 amino acids of any peptide can be inserted in the central immunodominant c/e1 epitope region of HbcAg and such chimeric particles induced B and T cell immune responses against the inserted epitopes (See abstract, in particular). The '002 patent teaches that the advantage of carrier is that it functions for enhance immunogenicity, providing protein stability and retains the ability to replicate while the incorporated protein segment has the potential for inducing the specific immune response (See column 2, lines 55-62, in particular).

19. No claim is allowed.
20. Any inquiry concerning this communication or earlier communications from the examiner should be directed to "Neon" Phuong Huynh whose telephone number is (703) 308-4844. The examiner can normally be reached Monday through Friday from 9:00 am to 6:00 p.m. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist (customer service) whose telephone number is (703) 872-9305.

Art Unit: 1644


21. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-7401. The IFW official Fax number is (703) 872-9306. For After Final, the Fax number is (703) 872-9307.

Phuong N. Huynh, Ph.D.

Patent Examiner

Technology Center 1600

November 17, 2003


CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600